Physician profile
David P Schenkein
NPI 1144330176
$4,964,416.77
in general payments reported to CMS, 2019-2025
9 companies · $920K in 2025
The $920K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $750K · 2021: $261K · 2022: $574K · 2023: $1.6M · 2024: $830K · 2025: $920K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2.6M · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $720K · Travel and Lodging: $48K · Food and Beverage: $5,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,604,575.03 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $719,754.62 |
| Travel and Lodging | $47,968.01 |
| Food and Beverage | $5,696.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $2,591,221.14 | 2020-2025 | |
| Agios Pharmaceuticals, INC. | $1,426,820.15 | 2020-2025 | Pyrukynd |
| Beigene, Ltd. | $814,668.04 | 2020-2025 | |
| Beone Medicines Ltd. | $122,201.14 | 2025 | |
| Beone Medicines USA, INC. | $8,750.00 | 2025 | |
| Genentech, INC. | $596.07 | 2019 | |
| Bristol Myers Squibb Company | $104.28 | 2019 | |
| Glaxosmithkline, LLC. | $35.33 | 2019 | |
| Cortex, INC. | $20.62 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,832,856.66 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schenkein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.